6-KThe Wire
Alpha Tau Medical Ltd. files 6-K
Filed May 5, 2026 · 3mo ago · Accession 0001213900-26-051929
Plain English
Alpha Tau Medical Ltd. announced upcoming presentation of study results for its Alpha DaRT® technology in combination with Pembrolizumab for head and neck cancer at the AHNS 12th International Conference on Head and Neck Cancer.
Filing details
- Company
- Alpha Tau Medical Ltd.
- Ticker
- DRTS
- CIK
- 1871321
- Form type
- 6-K
- Filing date
- May 5, 2026
- Report date
- May 5, 2026
- Document
- ea0289093-6k_alphatau.htm
- Size
- 29 KB